Tumor-permeable smart liposomes by modulating the tumor microenvironment to improve the chemotherapy

Widjaya, Andy Samuel; Yun-hu, Liu; Yang, Yueying; Yin, Weiwei; Liang, Jin-Yu; Jiang, Yanyan

doi:10.1016/j.jconrel.2022.02.020

Cited by 26 publications

(16 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Certain chemodrugs can modulate the microenvironment of cold tumors by providing tumor antigens via inducing ICD of tumor cells [ 7 , 39 ] or by stimulating APCs to promote the cancer-immune cycle. PTX and Gem are two interesting candidates with potential synergistic effects when co-loaded into robust micelles.…”

Section: Resultsmentioning

confidence: 99%

“…The past years have witnessed various “heating up” strategies e.g. by generating tumor antigens with immunogenic cell death (ICD)-inducing chemotherapy, radiotherapy or photodynamic therapy [ 7 , 8 ], trafficking or activating immune cells [ 9 , 10 ], reducing or repolarizing immunosuppressive immune cells [ 11 , 12 ] and remodeling extracellular matrix (ECM) barrier [ 13 ]. A couple of chemical drugs like doxorubicin (Dox), paclitaxel (PTX), and oxaliplatin were reported to “heat up” the immune microenvironment by inducing ICD, which led to exposure of calreticulin (CRT) and release of adenosine triphosphate (ATP) and high mobility group box chromosomal protein 1 (HMGB1) [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

“…by generating tumor antigens with immunogenic cell death (ICD)-inducing chemotherapy, radiotherapy or photodynamic therapy [ 7 , 8 ], trafficking or activating immune cells [ 9 , 10 ], reducing or repolarizing immunosuppressive immune cells [ 11 , 12 ] and remodeling extracellular matrix (ECM) barrier [ 13 ]. A couple of chemical drugs like doxorubicin (Dox), paclitaxel (PTX), and oxaliplatin were reported to “heat up” the immune microenvironment by inducing ICD, which led to exposure of calreticulin (CRT) and release of adenosine triphosphate (ATP) and high mobility group box chromosomal protein 1 (HMGB1) [ 7 ]. For example, Huang et al reported the significantly upregulated ICD of 4T1 tumors when treated with Dox (5 mg/kg) and further primed TME in combined with CXC chemokine receptor 4 (CXCR4)-inhibition, resulting in improved anti-PD-L1 therapy [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Co-delivery of gemcitabine and paclitaxel plus NanoCpG empowers chemoimmunotherapy of postoperative “cold” triple-negative breast cancer

Guo

Zhao

et al. 2023

Bioactive Materials

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Co-delivery of gemcitabine and paclitaxel plus NanoCpG empowers chemoimmunotherapy of postoperative “cold” triple-negative breast cancer

Guo

Zhao

et al. 2023

Bioactive Materials

View full text Add to dashboard Cite

“…[ 28 ] As the first nanosystem (DOXIL (PEGylated liposomal doxorubicin)) approved for clinical use in 1995, [ 29 ] liposomes have received extensive attention in the biomedical field as nanocarriers. At present, eight liposome drugs have been approved for cancer treatment, [ 30 ] and they have played an important role in recent years. The effective mRNA vaccine is also encapsulated by liposomes, [ 31 ] which indicates that liposomes are promising candidates in nanomedicines.…”

Section: Targeted Nanomaterials Without a Stimulus‐response For Cance...mentioning

confidence: 99%

Cancer Immunotherapy Elicited by Immunogenic Cell Death Based on Smart Nanomaterials

et al. 2023

View full text Add to dashboard Cite

Cancer immunotherapy has been a revolutionary cancer treatment modality because it can not only eliminate primary tumors but also prevent metastases and recurrent tumors. Immunogenic cell death (ICD) induced by various treatment modalities, including chemotherapy, phototherapy, and radiotherapy, converts dead cancer cells into therapeutic vaccines, eliciting a systemic antigen‐specific antitumor. However, the outcome effect of cancer immunotherapy induced by ICD has been limited due to the low accumulation efficiency of ICD inducers in the tumor site and concomitant damage to normal tissues. The boom in smart nanomaterials is conducive to overcoming these hurdles owing to their virtues of good stability, targeted lesion site, high bioavailability, on‐demand release, and good biocompatibility. Herein, the design of targeted nanomaterials, various ICD inducers, and the applications of nanomaterials responsive to different stimuli, including pH, enzymes, reactive oxygen species, or dual responses are summarized. Furthermore, the prospect and challenges are briefly outlined to provide reference and inspiration for designing novel smart nanomaterials for immunotherapy induced by ICD.

show abstract

“…A liposome encapsulating daunorubicin and cytarabine (VYXEOS), in a ratio of 5:1, is used worldwide for acute myeloid leukemia in adults (Blair 2018 ). Paclitaxel loaded Liposome, demonstrated advantage compared to non NPs in tumor drug accumulation, penetration via suppression of tumor inflammation and immunosuppressive TME (Widjaya et al 2022 ). The liposome got FDA approval when it exhibited clinical efficacy in elderly diagnosed with AML in phase-3 clinical trial (Table 2 ).…”

Section: Nanoparticles In Inflammationmentioning

confidence: 99%

Nanomedicines: intervention in inflammatory pathways of cancer

Anwar

Naqvi

Shams³

et al. 2023

Inflammopharmacol

View full text Add to dashboard Cite

Inflammation is a complex defense process that maintains tissue homeostasis. However, this complex cascade, if lasts long, may contribute to pathogenesis of several diseases. Chronic inflammation has been exhaustively studied in the last few decades, for its contribution in development and progression of cancer. The intrinsic limitations of conventional anti-inflammatory and anti-cancer therapies triggered the development of nanomedicines for more effective and safer therapies. Targeting inflammation and tumor cells by nanoparticles, encapsulated with active therapeutic agents, offers a promising outcome with patient survival. Considerable technological success has been achieved in this field through exploitation of tumor microenvironment, and recognition of molecules overexpressed on endothelial cells or macrophages, through enhanced vascular permeability, or by rendering biomimetic approach to nanoparticles. This review focusses on the inflammatory pathways in progression of a tumor, and advancement in nanotechnologies targeting these pathways. We also aim to identify the gaps that hinder the successful clinical translation of nanotherapeutics with further clinical studies that will allow oncologist to precisely identify the patients who may be benefited from nanotherapy at time when promotion or progression of tumor initiates. It is postulated that the nanomedicines, in near future, will shift the paradigm of cancer treatment and improve patient survival. Graphical abstract

show abstract

Tumor-permeable smart liposomes by modulating the tumor microenvironment to improve the chemotherapy

Cited by 26 publications

References 50 publications

Co-delivery of gemcitabine and paclitaxel plus NanoCpG empowers chemoimmunotherapy of postoperative “cold” triple-negative breast cancer

Co-delivery of gemcitabine and paclitaxel plus NanoCpG empowers chemoimmunotherapy of postoperative “cold” triple-negative breast cancer

Cancer Immunotherapy Elicited by Immunogenic Cell Death Based on Smart Nanomaterials

Nanomedicines: intervention in inflammatory pathways of cancer

Contact Info

Product

Resources

About